These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25804613)

  • 1. Prevalence of JAK2V617F mutation in deep venous thrombosis patients and its clinical significance as a thrombophilic risk factor: Indian perspective.
    Singh N; Sharma A; Sazawal S; Ahuja A; Upadhyay A; Mahapatra M; Saxena R
    Clin Appl Thromb Hemost; 2015 Sep; 21(6):579-83. PubMed ID: 25804613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
    Pardanani A; Lasho TL; Hussein K; Schwager SM; Finke CM; Pruthi RK; Tefferi A
    Mayo Clin Proc; 2008 Apr; 83(4):457-9. PubMed ID: 18380991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2V617F mutation prevalence on Chilean adults suffering from primary mesenteric and portal venous thromboses.
    González-Montero J; Del Valle-Batalla L; Castillo-Astorga R; Marín Valdés A; Conte Lanza G
    Int J Lab Hematol; 2020 Jun; 42(3):331-334. PubMed ID: 32154655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of the JAK2 46/1 haplotype with non-splanchnic venous thrombosis.
    Zerjavic K; Zagradisnik B; Lokar L; Krasevac MG; Vokac NK
    Thromb Res; 2013 Aug; 132(2):e86-93. PubMed ID: 23845539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK2V617F mutation in patients with splanchnic vein thrombosis.
    Xavier SG; Gadelha T; Pimenta G; Eugenio AM; Ribeiro DD; Gomes FM; Bonamino M; Zalcberg IR; Spector N
    Dig Dis Sci; 2010 Jun; 55(6):1770-7. PubMed ID: 19690956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives.
    Aznar J; Vayá A; Estellés A; Mira Y; Seguí R; Villa P; Ferrando F; Falcó C; Corella D; España F
    Haematologica; 2000 Dec; 85(12):1271-6. PubMed ID: 11114134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
    Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
    J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg.
    Lauw MN; Bus EW; van Wulfften Palthe AF; Coppens M; Homburg CH; Middeldorp S; van der Schoot CE; Koene HR; Biemond BJ
    Ann Hematol; 2012 Jan; 91(1):103-7. PubMed ID: 21484303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities.
    Martinelli I; Battaglioli T; Bucciarelli P; Passamonti SM; Mannucci PM
    Circulation; 2004 Aug; 110(5):566-70. PubMed ID: 15262837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inferior vena cava thrombosis and its relationship with the JAK2V617F mutation and chronic myeloproliferative disease.
    Linnemann B; Kraft C; Roskos M; Zgouras D; Lindhoff-Last E
    Thromb Res; 2012 Jun; 129(6):720-4. PubMed ID: 21982959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.
    Santamaria MG; Agnelli G; Taliani MR; Prandoni P; Moia M; Bazzan M; Guazzaloca G; Ageno W; Bertoldi A; Silingardi M; Tomasi C; Ambrosio GB;
    Thromb Res; 2005; 116(4):301-6. PubMed ID: 16038714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders.
    Marchetti M; Falanga A
    Pathophysiol Haemost Thromb; 2008; 36(3-4):148-59. PubMed ID: 19176988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis.
    Qi X; Yang Z; Bai M; Shi X; Han G; Fan D
    Aliment Pharmacol Ther; 2011 May; 33(10):1087-103. PubMed ID: 21395632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hereditary thrombophilia in an unselected cohort of venous thrombosis patients in Singapore.
    Lee LH; Liu TC; Kuperan P; Tan LK; Tan D; Poon ML; Ong KH; Fong SZ; Tan MY; Ng HJ
    J Clin Pathol; 2011 Sep; 64(9):814-7. PubMed ID: 21593345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombophilia differences in cerebral venous sinus and lower extremity deep venous thrombosis.
    Wysokinska EM; Wysokinski WE; Brown RD; Karnicki K; Gosk-Beirska I; Grill D; McBane RD
    Neurology; 2008 Feb; 70(8):627-33. PubMed ID: 18285537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: a prospective study.
    Qi X; Zhang C; Han G; Zhang W; He C; Yin Z; Liu Z; Bai W; Li R; Bai M; Yang Z; Wu K; Fan D
    J Gastroenterol Hepatol; 2012 Jun; 27(6):1036-43. PubMed ID: 22142461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombophilia as a multigenic disease.
    Zöller B; García de Frutos P; Hillarp A; Dahlbäck B
    Haematologica; 1999 Jan; 84(1):59-70. PubMed ID: 10091393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms.
    Fiorini A; Chiusolo P; Rossi E; Za T; De Ritis DG; Ciminello A; Leone G; De Stefano V
    Am J Hematol; 2009 Feb; 84(2):126-7. PubMed ID: 19105231
    [No Abstract]   [Full Text] [Related]  

  • 19. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder.
    Pardanani A; Lasho TL; Schwager S; Finke C; Hussein K; Pruthi RK; Tefferi A
    Leukemia; 2007 Aug; 21(8):1828-9. PubMed ID: 17460706
    [No Abstract]   [Full Text] [Related]  

  • 20. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.
    De Stefano V; Martinelli I; Mannucci PM; Paciaroni K; Chiusolo P; Casorelli I; Rossi E; Leone G
    N Engl J Med; 1999 Sep; 341(11):801-6. PubMed ID: 10477778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.